NCT00551213View on ClinicalTrials.gov

A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 21, 2007

Primary Completion Date

June 4, 2009

Study Completion Date

June 4, 2009

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL

Robatumumab

DRUG

Irinotecan

BIOLOGICAL

Cetuximab

DRUG

Capecitabine

DRUG

FOLFOX

Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)

DRUG

CAPEOX/XELOX

Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)

DRUG

FOLFIRI

Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00551213 - A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) | Biotech Hunter | Biotech Hunter